Amerise Biosciences Share Price
0.86+0.04 (+4.88%)
+21.13% past 1 Year
Amradeep Industries Ltd is a specialized manufacturer of high quality construction equipment and agricultural equipment. The company is also engaged in commodity trading
Corporate filings & documents
Announcements
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are submitting herewith the Annual Report of the Company for the financial year 2025-26 along with the Notice of 41st Annual General Meeting to be held on Thursday 24th September 2026
3 days agoPursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are submitting herewith the Annual Report of the Company for the financial year 2025-26 along with the Notice of 41st Annual General Meeting to be held on Thursday 24th September 2026
3 days agoPFA
3 days agoPFA
3 days agoPFA
3 days agoPFA
3 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
2 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
2 weeks agoPFA
1 month agoPFA
1 month agoPFA
1 month agoPFA
1 month agoPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Monday 3rd August 2026. at the Registered Office of the Company and transacted the following major businesses:1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June 2026.The board meeting commented at 04:50 PM and concluded at 05:10 PMPlease take the above intimation in your records.Thanking You
1 month agoPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Monday 3rd August 2026. at the Registered Office of the Company and transacted the following major businesses:1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June 2026.The board meeting commented at 04:50 PM and concluded at 05:10 PMPlease take the above intimation in your records.Thanking You
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoAmerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Monday 3rd August 2026 inter alia to consider following businesses: -1.) To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2026.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
1 month agoAmerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Monday 3rd August 2026 inter alia to consider following businesses: -1.) To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2026.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
1 month agoPFA
1 month agoPFA
1 month agoPFA
2 months agoPFA
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
3 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
3 months agoPFA
4 months agoPFA
4 months agoThis is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Tuesday 5th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations 2015 has been approved by the Board of Directors of the Company and taken on record inter-alia the following items;1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March 2026.2.) Independent Auditors Report in pursuance with Regulation 33 of SEBI (LODR) Regulations 2015 for the F.Y. 31st March 2026.Further we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 for the financial year ended on March 31 2026 with Unmodified Opinion. The board meeting commenced at 04.45 PM and concluded at 05:15 PM.We request you to kindly take on record the same.Thanking You.
4 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
4 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
4 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
4 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Snehjeev Ventures Pvt Ltd & PACs
4 months agoAmerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held onTuesday 5th May 2026 inter alia to consider following businesses: -1.) Approve and take on record the Audited Standalone Financial Results of the Company for the quarterand year ended on 31st March 2026 along with the Reports of the Auditors thereon.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
4 months agoAmerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held onTuesday 5th May 2026 inter alia to consider following businesses: -1.) Approve and take on record the Audited Standalone Financial Results of the Company for the quarterand year ended on 31st March 2026 along with the Reports of the Auditors thereon.2.) Any other matter with the permission of the board which the Board may think fit.Please take the above intimation in your records.Thanking You.
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Amerise Biosciences Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L29199GJ1984PLC007195</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: SONI PANDIYA <br/> Designation: COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: ALBERT HINES <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 22/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Amerise Biosciences Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L29199GJ1984PLC007195</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: SONI PANDIYA <br/> Designation: COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: ALBERT HINES <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 22/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoPFA
4 months agoPFA
4 months agoPFA
4 months agoPFA
5 months agoPFA
5 months agoPFA
5 months agoPFA
7 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
24 , Laxmi Chambers Navjeevan Press Road Opp . Old Gujarat High Court Ahmedabad Gujarat PIN: 380014 Tel No: NULL Fax No: NULL Email: [email protected] Internet: www.amerisebiosciencesltd.site
Registrars
Office No A 106 & 107, Dattani Plaza, East West Compound, Andheri Kurla Road,Safedpul, Sakinaka, Mumbai-400072022-28520461/462 Office No A 106 & 107, Dattani Plaza East West Compound, Andheri Kurla Road Safedpul, Sakinaka PIN: Tel No: 022-28520461/462 Fax No: NULL Email: [email protected]
Management
Kelash Bunkar, Non Executive Independent Director
Manisha Patel, Non Executive Independent Director
Soni Pandiya, Company Secretary & Compliance Officer
Details
BSE 531681
NSE NULL
ISIN INE673C01020